The "Right to Try Individualized Treatments Act" is a new legislative measure aimed at providing individuals with life-threatening or severely debilitating illnesses the opportunity to access individualized investigational treatments. The bill defines key terms such as "eligible facility," "eligible patient," and "individualized investigational treatment," establishing criteria for patients to qualify for these treatments. Eligible patients must have a life-threatening illness, have exhausted all other FDA-approved treatment options, and receive a recommendation from their physician for a treatment tailored to their genetic profile. The act allows manufacturers to provide these treatments either for free or at a cost to the patient, contingent upon informed consent that outlines the risks and financial responsibilities associated with the treatment.

Additionally, the act includes provisions to protect healthcare providers from disciplinary actions related to their recommendations for individualized treatments and ensures that patients' heirs are not liable for debts incurred from such treatments if the patient dies. It also prohibits state officials from obstructing access to these investigational treatments and clarifies that the act does not create a private cause of action against manufacturers or healthcare providers, provided they comply with the act's terms. Furthermore, the act does not mandate insurance coverage for these treatments, nor does it require healthcare facilities to provide additional services without approval.